Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Last Shall be First? The Federal Coordinating Committee for Comparative Effectiveness Research

This article was originally published in RPM Report

Executive Summary

The Department of Health & Human Services announced the 15 member coordinating committee to oversee the $1.1 billion in new spending on comparative effectiveness research included in the stimulus bill. Here are the members, as presented by HHS in its official announcement March 19. There's no way to know for sure who will have the most impact, but it's a safe bet that you can start at the bottom in this case. Ezekiel Emanuel has emerged as a key health policy advisor in the Obama White House-and his brother is the chief of staff.

You may also be interested in...

Cost Effectiveness in the US? Round One Goes Against Pharma

The stimulus bill provides an unprecedented $1.1 billion for comparative effectiveness research-and does so with none of the key provisions biopharma companies hope to see as the US federal government takes a more active role in the field. The good news: this is only the first round, and there is reason to believe the field is evolving as most pharma companies would want. But this isn't the time for manufacturers to let their guard down.

QUOTED. 25 January. 2021. Scott Whitaker.

US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts